VIBRA试验:家庭当日启动抗逆转录病毒治疗后村级续药对比诊所续药对莱索托农村HIV感染者病毒抑制的影响——整群随机临床试验方案
VIBRA试验是在莱索托两个地区开展的整群随机平行组优效性临床试验,比较家庭当日启动抗逆转录病毒治疗后村级续药模式与标准诊所续药对HIV感染者12个月病毒抑制的影响,目标样本量至少262人。
要点
- 整群随机对照试验,比较村级卫生工作者续药联合短信提醒与标准诊所续药。
- 主要终点为入组后12个月病毒抑制,次要终点包括 linkage to and engagement in care。
- 最低目标样本量262人,统计分析遵循CONSORT指南。
核心结论
- VIBRA试验旨在评估家庭当日启动抗逆转录病毒治疗后多组分差异化抗逆转录病毒治疗交付模式(VIBRA模式)的有效性。
研究设计与样本
- 整群随机平行组优效性临床试验,在莱索托两个地区开展,按地区、村庄规模和村庄至最近卫生机构可及性分层。
- 集群(村庄)随机分配至VIBRA模式或标准 care,最低目标样本量262名参与者。
- 合格个体为社区HIV检测中发现的HIV阳性、年龄10岁及以上且未服用抗逆转录病毒治疗者,提供家庭当日启动抗逆转录病毒治疗。
主要发现
- 干预集群提供差异化抗逆转录病毒治疗交付包,包括由经过培训和监督的村级卫生工作者进行药物续药和随访,以及通过短信接收个体化定制的依从性提醒和病毒载量结果通知。
- 对照集群继续接受标准 care,即从诊所领取抗逆转录病毒治疗续药且无短信通知。
- 主要终点为入组后12个月病毒抑制,次要终点包括 linkage to and engagement in care。
- 计划进行安全性和成本效果分析以及定性研究。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: There is a need for evaluating community-based antiretroviral therapy (ART) delivery models to improve overall performance of HIV programs, specifically in populations that may have difficulties to access continuous care. This cluster-randomized clinical trial aims to evaluate the effectiveness of a multicomponent differentiated ART delivery model (VIBRA model) after home-based same-day ART initiation in remote villages in Lesotho, southern Africa. METHODS/DESIGN: The VIBRA trial (VIllage-Based Refill of ART) is a cluster-randomized parallel-group superiority clinical trial conducted in two districts in Lesotho, southern Africa. Clusters (i.e., villages) are randomly assigned to either the VIBRA model or standard care. The clusters are stratified by district, village size, and village access to the nearest health facility. Eligible individuals (HIV-positive, aged 10 years or older, and not taking ART) identified during community-based HIV testing campaigns are offered same-day home-based ART initiation. The intervention clusters offer a differentiated ART delivery package with two features: (1) drug refills and follow-ups by trained and supervised village health workers (VHWs) and (2) the option of receiving individually tailored adherence reminders and notifications of viral load results via SMS. The control clusters will continue to receive standard care, i.e., collecting ART refills from a clinic and no SMS notifications. The primary endpoint is viral suppression 12 months after enrolment. Secondary endpoints include linkage to and engagement in care. Furthermore, safety and cost-effectiveness analyses plus qualitative research are planned. The minimum target sample size is 262 participants. The statistical analyses will follow the CONSORT guidelines. The VIBRA trial is linked to another trial, the HOSENG (HOme-based SElf-testiNG) trial, both of which are within the GET ON (GETing tOwards Ninety) research project. DISCUSSION: The VIBRA trial is among the first to evaluate the delivery of ART by VHWs immediately after ART initiation. It assesses the entire HIV care cascade from testing to viral suppression. As most countries in sub-Saharan Africa have cadres like the VHW program in Lesotho, this model-if shown to be effective-has the potential to be scaled up. The system impact evaluation will provide valuable cost estimations, and the qualitative research will suggest how the model could be further modified to optimize its impact. TRIAL REGISTRATION: Clinicaltrials.gov, NCT03630549 . Registered on 15 August 2018.
引用
- Amstutz A, Lejone TI, Khesa L, et al. VIBRA trial - Effect of village-based refill of ART following home-based same-day ART initiation vs clinic-based ART refill on viral suppression among individuals living with HIV: protocol of a cluster-randomized clinical trial in rural Lesotho. Trials. 2019. PMID: 31439004. doi:10.1186/s13063-019-3510-5
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。